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Abstract
Aim: Oxidative stress is strongly implicated in many psychiatric disorders, which has
resulted in the development of new interventions to attempt to perturb this pathol-
ogy. A great deal of attention has been paid to glutathione, which is the brain's domi-
nant antioxidant and plays a fundamental role in removing free radicals and other
reactive oxygen species. Measurement of glutathione concentration in the brain
in vivo can provide information on redox status and potential for oxidative stress to
develop. Glutathione might also represent a marker to assess treatment response.
Methods: This paper systematically reviews studies that assess glutathione concen-
tration (measured using magnetic resonance spectroscopy) in various mental health
conditions.
Results: There is limited evidence showing altered brain glutathione concentration in
mental disorders; the best evidence suggests glutathione is decreased in depression,
but is not altered in bipolar disorder. The review then outlines the various methodo-
logical options for acquiring glutathione data using spectroscopy.
Conclusions: Analysis of the minimum effect size measurable in existing studies indi-
cates that increased number of participants is required to measure subtle but possibly
important differences and move the field forward.
K E YWORD S
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1 | INTRODUCTION
There is now extensive evidence that oxidative stress, defined as a
disturbance in the balance between the production of reactive oxygen
species and antioxidant defences (Betteridge, 2000) plays a role in the
pathophysiology of many psychiatric disorders, including depression,
bipolar disorder, anxiety and schizophrenia (Smaga et al., 2015). For
example, depressed patients display increased markers of oxidative
stress in plasma with an associated decrease in total antioxidant
capacity (Gałecki, Szemraj, Bienkiewicz, Florkowski, & Gałecka, 2009)
(Yumru et al., 2009), and similar findings have been reported in anxi-
ety (Atmaca, Kuloglu, Tezcan, & Ustundag, 2008) and schizophrenia
(Akiibinu, Ogundahunsi, & Ogunyemi, 2012; Dietrich-Muszalska, Olas,
Głowacki, & Bald, 2009). The result of this oxidative stress is cellular
damage, with consequent impacts on cell function or even cell death.
The presence of markers of oxidative stress across diagnostic groups
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suggests some common pathophysiological process that might be
amenable to universal treatment, an approach that would be particu-
larly helpful in the early stages of mental illness when specific diagno-
ses have not yet crystalized (McGorry, Hickie, Yung, Pantelis, &
Jackson, 2006).
The primary focus of much research in this area has been glutathi-
one (GSH). GSH is the brain's dominant antioxidant, and plays a fun-
damental role in removing free radicals and other reactive oxygen
species (Wood, Yücel, Pantelis, & Berk, 2009). Both reduced (GSH)
and oxidized (GSSG) GSH are present in cerebral tissue. Reduced GSH
is converted to GSSG either directly or through catalysis by glutathi-
one peroxidase (GPx) (Xin et al., 2016), upon interaction with a radical
species. This process is protective for cells and intracellular cellular
components against damage. GSSG is subsequently reduced back to
GSH, a reaction catalysed by glutathione reductase (GR), and in this
way GSH contributes to regulation and maintenance of cellular redox
status (Lushchak, 2012). The ratio of the redox active couple (GSH-
GSSG) can be used directly to measure oxidative stress, but precise
quantification of this ratio is challenging, even in blood measures, so
that GPx and GR assessment are frequently used instead (Xin et al.,
2016). In post-mortem studies of the prefrontal cortex (PFC) of
patients and non-psychiatric controls, GSH, GPx and GR alterations
were associated with bipolar disorder, major depressive disorder and
schizophrenia (Gawryluk, Wang, Andreazza, Shao, Yatham et al.,
2011; Gawryluk, Wang, Andreazza, Shao, & Young, 2011). While
direct measurement of these metabolites can be conducted in brain
post-mortem, in vivo quantification generally remains extremely chal-
lenging; however, GSH concentration in the brain can be assessed
using magnetic resonance spectroscopy (MRS).
This review therefore aims to integrate the results of published
studies employing MRS measurement of GSH in the brains of those
presenting with mental illness, particularly young people. Two main
questions will be addressed in this review:
1. Is perturbed GSH reliably associated with indicators of mental ill-
ness in young people, such as diagnosis, symptoms or functioning?
2. What are the strengths and weaknesses of the various approaches
to the in vivo quantification of GSH concentration using MRS?
These two questions are of importance to ongoing and planned
investigations regarding aetiology and prognosis in youth mental
health. Simultaneously, the optimal GSH measurement protocols that
utilize MRS are paramount. In order to address these questions, a sys-
tematic review was conducted selecting those publications that con-
tained human in vivo neurological MRS studies in which cerebral GSH
concentration was a target metabolite considered as a possible marker
of mental health conditions.
2 | METHODS
This systematic review followed PRISMA guidelines (Moher et al.,
2009) (Figure 1). However, due to the recent and emerging nature of
the outcome measures, no quantitative meta-analysis was conducted
on the resulting data.
2.1 | Databases and search terms
The review aims to provide information that will inform the design
and parameters of an investigation into the role of GSH in the quanti-
fication of neurological markers associated with conditions relating to
youth mental health. Such a study would require that optimal parame-
ters to assess GSH concentration in small regions of interest within
the brain, using standard, routine, clinical infrastructure currently
available. Studies considered within the present review were limited
to those published after 2000 in order to restrict results to technically
relevant procedures.
Four databases were identified for search, three of which pro-
vided general coverage (Web of Science, ScienceDirect and Scopus)
and one of which was medically focussed (PubMed). Records were
requested from each database (as of July 16, 2018) using the same
search terminology and using a breadth-first approach to ensure suffi-
cient coverage. Three sub-strings were required, each arising from a
range of alternatives: the population of interest (“youth mental health”
OR “anxiety” OR “bipolar” OR “depression” OR “psychosis” OR
“schizophrenia”), the measurement technique (“MRS” OR “magnetic
resonance” OR “spectroscopy”) and the comparative measure, in this
case a target metabolite (“GSH” OR “Glutathione”), were required
(AND) in the title or abstract (where possible) of the publications
returned.
The database search returned 264 studies in total (WoS:82, Sd:35,
Sc:98, PM:49) 103 of which were identified as duplicate studies (ie,
the same paper was present within the studies returned from two or
more data bases). The remaining studies were assessed for relevance.
Inclusion criteria were reasonably broad, requiring human study-
participants undergoing in vivo MRS of brain GSH with quantitative
outcomes and accessible full-text material. From the considered stud-
ies, 108 were rejected as they did not meet these criteria, while nine
were not assessed (as they were not appropriate for the analysis) leav-
ing 49 studies of relevance to this review.
3 | RESULTS
Relevant features (deemed important variables for the review)
extracted from studies are shown in Table 1.
Those studies that included quantitative comparisons (either tests
for significant differences or regression analysis) were rated according
to the minimum effect size required to achieve a power of 0.8, given a
significance value of less than 0.05. Using a simplified simulation,1
multiple realizations of participants were drawn from either:
• Two unit-variance normal distributions with mean separation
dμ = μ1 − μ1, or
• A two-element, zero-mean, multivariate normal with covari-
ance Σ=
1 dσ
dσ 1
 
.
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The effect size (dμ) or covariance (dσ) was then increased from zero
until at least 80% of 1 × 104 trials returned a result with a two-tailed
significance of less than 0.05. Results are shown in Table 1 as dmin
(where dσ is only shown for single-group studies).
3.1 | Non-quantitative outcomes
3.1.1 | GSH and cerebral GSH Concentration
Given that GSH is the major free radical scavenger within the brain,
that the GSH redox couple have been associated with psychiatric dis-
orders, and that GSH may be directly measured using sophisticated
MRS sequences in vivo within patient brains, a number of studies
have been performed that probe this connection. However, due to
the fact that there is considerable heterogeneity in methods for MRS
data acquisition, most studies differ in voxel size and placement,
parameters and post-processing, and also the quantitative measures
used to assess study outcomes. Therefore, it is not feasible to perform
quantitative analysis on acquired results. However, there are a num-
ber of conclusions that can be drawn from the data by summarizing
the main findings of the studies conducted in this domain. Here atten-
tion is divided between discussion of the evidence regarding the role
of GSH in the context of mental illness and the utility of MRS in the
measurement of this metabolite in vivo.
3.1.2 | Findings of in vivo GSH and mental illness
The majority of the studies (37) were aimed at determining if GSH
concentration significantly differed between healthy cohorts and
those with diagnosed mental disorders, or if there were specific alter-
ations by diagnostic sub-group. A second group of studies (7) were
targeted at novel approaches to spectral measurement and
Initial search
OR (‘youth mental health’, ‘anxiety’, ‘bipolar’, ‘depression’, ‘psychosis’, 
‘schizophrenia’) AND
OR (‘MRS’, ‘magnetic resonance’, ‘spectroscopy’) AND
OR (‘GSH’, ‘glutathione’)
82- ISI WoS
49- PubMed
35- Science Direct
98- Scopus
= 264 manuscripts
Accepted
(49 manuscripts)
Rejected
(220 manuscripts)
Near-miss (out): 17
Editorial/ theory: 35
No full-text: 14
No brain MRS: 16
Duplicates :103
Animal study: 35
39 clear relevance
5 (added at review)
5 close-call (in)
Bipolar (8)
Schizophrenia (6)
Early/ first-episode psychosis (5)
Major depression (4)
Age-related (5)
Validation studies (9)
Clinical high-risk for psychosis (3)
Suicidal behaviour (1)
Chronic fatigue (1)
Autism (1)
PTSD (1)
Emerging bi/ unipolar (1)
Mood (1)
Anorexia (1)
Prader-Willi (1)
Multiple conditions (1)
F IGURE 1 Flow diagram representing
the database search with relevant
accepted manuscripts considered in this
investigation. PTSD, post traumatic stress
disorder
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TABLE 1 In vivo MRS of GSH for mental health: summary of findings
Condition Brain
region
MR-Sq Study and main finding #Part. dmin Other GSH-specific correlations
BD ACC 3 T PRESS (Lagopoulos et al., 2013)
• No difference in GSH between
patients and controls:
• (t(115) = 1.253, P = .213).
53 (BD)
51 (HC)
0.6 GSH vs YMRS: (ρ = −0.198; P = .214;
N = 41) GSH vs HDRS: (ρ = 0.127;
P = .385; N = 49)
GSH vs age of onset: (ρ = −0.09;
P = .522; N = 53)
GSH vs duration (ρ = −0.125;
P = .374; N = 53).
3 T PRESS (Chitty, Lagopoulos, et al., 2013)
• Risky drinking in patients showed
less GSH than non-risky:
• (t(48) = 2.44, P = .015).
33 (BD)
17 (HC)
0.9 High alcohol use disorders
identification test score negatively
correlated with GSH in BD subjects
(r = −0.478, P = .005).
3 T PRESS (Chitty, Lagopoulos, Hickie, &
Hermens, 2015a, 2015b)
• Change in alcohol use, smoking
and age predict changes in GSH
(at 15 months):
• (F(3, 26) = 3.69, P < .05).
• Not controlled as comorbid.
30 (BD) 0.5 GSH vs alcohol frequency: r = −0.381,
P < .05 GSH vs smoking frequency:
r = −0.367, P < .05
3 T J-PRESS (Soeiro-de-Souza et al., 2016)
• No difference in GSH between
euthymic BD and controls.
• Lac / GSH in BD patients
50 (BD)
38 (HC)
0.6 Lac vs GSH
Patients: (B = 0.20, t = 3.2, P = .003
[0.07, 0.33]) Controls:(B = 0.17,
t = 0.64, P = .11 [0.04, 0.39])
ACC + Hip 3 T PRESS (Chitty, Lagopoulos, Hickie, &
Hermens, 2014)
• No difference in GSH in either
region between BD and Controls.
• Differences mediated by drinking
and smoking.
64 (BD)
49 (HC)
0.5 GSHHip vs risky drinking (BD):
(r = 0.489, P < .021) GSHACC vs
smoking (BD): (t(53) = 4.162,
P < .001)
l-Hip 3 T PRESS (Chitty et al., 2015b)
• Controls: mismatch negativity
correlated with GSH decrease in
both temporal sites.
• rleft = −0.542 [−0.8, −0.06]
• rright = −0.374 [−0.67, 0.07]
• No association in BD patients.
28 (BD)
22 (HC)
0.8 GSH vs left-MMN (r = 0.068, P = .74,
95% [−0.36, 0.69])
GSH vs right-MMN (r = −0.057,
P = .78, 95% [−0.52, 0.73]).
OCC +
mPFC
3 T SPECIAL (Godlewska, Yip, Near, Goodwin, &
Cowen, 2014)
• No difference between BP and
control in either region (for GSH
or other metabolites).
13 (BD)
11 (HC)
1.2
ACC
+ OCC
7 T STEAM (Masaki et al., 2016) After
treatment:
• No change in GSHOCC
• Decrease in GSHACC (P = .033)
• GSHACC plc. =1.31土 0.043
• GSHACC Ebselen = 1.17土0.07
20 (HC) 0.6
Schiz. (SZ) ACC 4 T STEAM (Terpstra et al., 2005)
• STEAM was within uncertainty of
edited spectra in in vivo
tests (P = .4).
• GSH levels of patients not
different from controls (P = .4,
differences >10%).
13 (SZ)
9 (HC)
1.3 GSHpat = 1.6土0.2
GSHcont. = 1.5土0.3
MEGA- PRESS
7 T STEAM (Brandt et al., 2016)
• GSH differences between
patients and controls under the
age of 40:
24 (SZ)
24 (HC)
0.8 GSH not correlated with age
Overall no GSH difference between
patients and controls.
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TABLE 1 (Continued)
• [t(25) = −2.47, P = .021]
ACC + LI
+ VC
7 T STEAM (Kumar et al., 2018)
• GSH lower in patients vs healthy
controls- only in ACC voxel
• ACC P = .008
• LI P = .784
• VC P = .464
28 (SCH)
45 (HC)
0.7 GSH and glutamine correlated in all
three voxels GSH vs ACC: r = 0.56
GSH vs LI: r = 0.80 GSH
vs VC: r = 0.65
mPFC 1.5 T PRESS (Do, Trabesinger et al.)
• Cerebrospinal fluid GSH sample
showed 27% decrease in
patients (P < .05).
• MRS showed 52% decrease in
patients (P < .0012).
14 (SZ)
14 (HC)
1.1
pMFC 3 T MEGA-
PRESS
(Matsuzawa et al., 2008)
• No significant difference
between patients and controls.
20 (SZ)
16 (HC)
1.0 For patients GSH correlated to
negative symptoms SANS and
BPRS (r = −0.68, P < .001) and
related to trail making test A
(P < .05).
Imag. 4 T proton echo
planar
spectroscopic
imaging
(Bustillo et al., 2011)
• No GSH-specific hypothesis
tested.
30 (SZ)
28 (HC)
0.8
Major
Depression
(MD)
OCC,
bilat.
3 T MEGA-
PRESS
(Lapidus et al., 2014)
• GSH negatively correlated to
anhedonia severity:
• (r = −0.55, P = .01).
11 (MD)
10 (HC)
1.3 MDD sample in isolation showed
associations between anhedonia
and GSH: (r = −0.53, P = .09).
No associations between fatigue
severity and GSH
OCC 3 T SPECIAL (Godlewska, Near, & Cowen, 2015)
• GSH was decreased in depressed
patients
• F = 5.10, P = .028
• F = 4.28, P = .042 (con. Age/sex)
39 (MD)
31 (HC)
0.7
3 T PRESS (Freed et al., 2017)
• GSH decreased in MD patients'
vs HCs
• P = .04
19 (MD)
8 (HC)
1.3 No correlation between GSH and
anhedonia, MD severity, or onset
Imag. 3 T MRSI (Li et al., 2016)
• In left putamen, GSH decreased
in patients (P = .044)
• Patient increase post therapy not
significant.
16 (MD)
10 (HC)
1.2 GSH/tCrpat. = 0.23士0.06
GSH/tCrcont. = 0.28士0.05
Early Psych.
(FEP/EP)
Temp 3 T PRESS (Berger et al., 2008)
• Bilateral GSH increase in
treatment group response
(F1,12 = 6.1, P = .03)
• No longer significant when
affective psychotic patients
removed.
24 (FEP) 0.6 PANSS negative symptom change
negatively correlated with GSH
(r = −0.57, P = .041).
Percent change in GSH and
Glutamate/Glutamine correlated:
(r = 0.64, P = .01)
3 T PRESS (Wood et al., 2009)
• GSH 22% higher in patients than
controls:
• (F1,46 = 4.7, P = .035).
• No difference in other tests:
hemisphere (P = .137),
group-by-hemisphere (P = .513).
30(FEP)
18(HC)
0.9 Patients not responding to topical
niacin show 35% higher GSH than
responders (F1,28 = 5.1, P = .007).
mPFC 3 T SPECIAL (Monin et al., 2015) 30 (EP)
40 (HC)
0.7
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• Potential dependence between
GSH levels and white matter
integrity during PFC
developments.
Controls: GSH correlated to general
FA (r = 0.34, P = .03) and
functional connectivity (r = 0.40,
P = .01).
Patients controlled for medication
and duration: GSH correlated to
general FA (0.31, P = .01).
3 T SPECIAL (Xin et al., 2016)
• GSH decrease (P = .006) in
glutamate-cysteine ligase
catalytic high-risk (1.15土 0.17)
compared to low-risk (1.34土0.8).
25 (EP)
33 (HC)
0.8 GSHmPFC correlated to GSHblood in
controls (P = .021) but not in
patients (P = .39).
CHR for
psychosis
mPFC 3 T PRESS (Hafizi et al., 2018)
• GSH and TSPO radioligand
significant negative association in
healthy volunteers, but not
clinical high-risk group—
indicative of an abnormal
interaction TSPO expression and
redox status in CHR group
27 (CHR)
21 (HC)
0.9 mPFC GSH and [18F]FEPPA VT
(radioligand of TSPO) not sig.
Different between groups.
3 T PRESS (Da Silva, Hafizi et al. 2018a)
• No sig difference between mPFC
GSH in drug-naïve patients vs
healthy controls
30 (CHR)
27 (HC)
0.8 No sig correlations between cerebral
GSH and clinical and
neuropsychological measures
No sig difference between GPx
activity and CHR vs HC (F = 0.15,
P = .70)
Significant effect lifetime cannabis
use in GPx activity (F = 7.41,
P = .01)
3 T PRESS (Da Silva et al., 2018)
• No sig difference between mPFC
GSH in drug-naïve patients vs
healthy controls
27 (CHR)
16 (HC)
0.9 No differences between microglial
activation and GSH between
groups
ACC
+
Striat.
3 T PRESS (Demro et al., 2017)
• GSHACC was shown to correlate
significantly with P3 (Grandiosity,
negative) and P5 (Disorganized
Communication, positive) as
measured by the SIPS
• GSHSTR was shown to
(negatively) correlate significantly
only to Grandiosity (P3)
12 (CHR) 0.7 GSH correlation with SIPS:
P1: rACC = −0.578 (0.062),
rSTR = −0.566 (0.088)
P2: rACC = −0.074 (0.828),
rSTR = −0.474 (0.167)
P3 rACC = −0.673 (0.023),
rSTR = −0.775 (0.009)
P4: rACC = −0.259 (0.441),
rSTR = −0.409 (0.241) P5:
rACC = 0.645 (0.032), rSTR = 0.138
(0.704)
Positive symptom sum:
rACC = −0.134 (0.695), rACC = −0.550
(0.099)
Age-related
(AD, Deprs-
at.risk, sleep-
apnea, and
MCI)
Th 3 T PRESS (Duffy et al., 2015)
• Older patients at risk of DEP
taking placebo had larger GSH/Cr
(t = 2.0, P = .049).
51 (DEP)
(28 treat+
23 plac.)
0.8 Increased GSHTh associated with
worsening symptoms (r = 0.43,
P = .043)
ACC 3 T PRESS (Duffy et al., 2015)
• Older patients at risk of DEP:
increased GSH in the ACC
(t = 2.7, P = .012)
58 (DEP)
12 (HC)
0.9 Depressed patients showed a
correlation between HADS
symptoms and GSH/Cr (r = 0.28,
P = .035).
Depressed patients showed a
negative correlation between verbal
6 FISHER ET AL.
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learning and GSH/Cr (r = −0.28,
P = .04)
3 T PRESS (Duffy et al., 2016)
• GSH/Cr correlated with
decreased executive function.
24 (ARD) 0.6 GSHACC vs Oxygen desat: r = −0.54,
P = .007 GSHACC vs
apnea-hypopnea: r = .42, P = .050
GSHACC vs response inhib: r = −.49,
P = .015. GSHACC vs set shifting:
r = −0.43, P = .37.
ACC
+ PCC
3 T PRESS (Duffy et al., 2014)
• MCI patients showed increased
levels of GSH in the cingulate:
• GSHACC (t = −2.2, P = .03)
• GSHPCC (t = −2.9, P = .05)
54 (MCI)
41 (HC)
0.6 MCI GSHACC: 0.47土 0.15 MCI
GSHPCC: 0.37土 0.07
Control GSHACC: 0.41土 0.10
Control GSHPCC: 0.29土 0.05
Vari. 3 T MEGA-
PRESS
(Mandal, Tripathi, & Sugunan, 2012)
• Female AD showed decreased
GSH in RFC (P = .003) compared
to young controls.
• Male AD showed decreased GSH
in the LFC
25 (ym)
20 (yf)
9 (om)
6 (of)
~1.3 GSHLFC different from GSHRFC in
young female (P = .02) and male
(P = .001) subjects.
GSHLFC vs GSHRFC: young females
(r = 0.641, P = .004)
(P = .05) compared to young
controls.
• Gender differences in GSH
distribution evident.
5 (mMCI)
6 (fMCI)
7 (mAD)
7 (fAD)
GSHLPC vs GSHRpC: young females
(r = 0.797, P = .000)
GSHLFC vs GSHLPC: young males
(r = 0.481, P = .032)
(Healthy young males/females
(ym/yf); healthy older
males/females (om/of);
males/females with mild cognitive
impairment and Alzheimer's
disease.)
Mult. ACC 3 T PRESS (Hermens, Lagopoulos, Naismith,
Tobias-Webb, & Hickie, 2012)
Clustering of patients based on
metabolites: 3 subgroups.
GSH responsible for cluster 2.
37 (DD)
29 (BP)
22 (PD)
25 (HC)
N/A Discriminant function 2 (40%
variance) characterized by GSH/Cr
(r = −0.753).
Suicidal
behaviour
dPFC 3 T SPECIAL (Jollant, Near, Turecki, &
Richard-Devantoy, 2016)
• No association was found
between GSH and suicidal
behaviour (F = 0.5, P = .6), but
associations with other
metabolites identified.
15 (SA)
10 (PC)
33 (HC)
~1.0 GSHdPFC Suicide Attempters: 0.24土
0.03 GSHdPFC Patient Controls:
0.23土 0.02 GSHdPFC Healthy
Controls: 0.23土0.03
Chronic fatigue OCC
+ Imag.
3 T MEGA-
PRESS/ MRSI
(Shungu et al., 2012)
• GSH deficits in patients with CFS
and MDD relative to controls:
• (F2,40 = 15.93; P < .001)
15 (CFS)
15 (MD)
13 (HC)
1.0 GSH was inversely correlated with
ventricular lactate (r = −0.545,
P = .001) and a range of key indices
of physical health.
Autism Basal
ganglia
+
dPFC
3 T PRESS (Durieux et al., 2016)
• No GSH difference observed
between patients and controls.
21 (ASD)
29 (HC)
0.8 Correlation between GSH and Autism
spectrum disorder was observed in
either region.
PTSD ACC
+ dLPFC
3 T MEGA-
PRESS
(Michels et al., 2014)
• Observed GSH levels 22.73%
higher in patients than controls
(F = 5.757, P = .025)
12 (PTS)
17 (HC)
1.1 GSHACC: PTSD = 0.15 ± 0.03,
Non = 0.11 ± 0.03 (d = 1.33)
GSHdLPFC: = 0.14 ± 0.03, Non = 0.11
± 0.03 (d = 1.00)
Emerging
Unipolar/Bi
polar
ACC 3 T PRESS (Naismith et al., 2014)
• GSH not associated with
unipolar/bipolar differentiation
(t = 1.15, P = .255).
53 (EBD) 0.4 GSH not associated with sleep
midpoint (r = 0.211, P = .151)
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Mood ACC +
HIPP
3 T PRESS (Hermens et al., 2018)
• Positive correlations between
Fractional Anisotropy in the stria
terminalis and GSHACC were
found across groups (r =
0.215, P < .01).
• DEP or BD in combination with
decreased GSHACC was
associated with reduced FA.
94 (DEP)
76 (BD)
59 (HC)
0.2 Decreased white matter integrity was
associated with decreased GSHHIPP.
Anorexia
Nervosa
ACC + OC
+ PUT
7 T STEAM (Godlewska et al., 2017)
• GSH levels unchanged between
groups.
13 (AN)
12 (HC) 1.2
AN (SEM) HC (SEM) p-value
GSHACC 1.19 (0.07) 1.27 (0.10) 0.38
CRLB 10.2 (2.9) 8.9 (2.8)
GSHOCC 0.95 (0.03) 0.94 (0.04) 0.85
CRLB 10.5 (3.0) 10.67 (3.08)
GSHPUT 1.51 (0.45) 1.10 (0.05) 0.43
CRLB 15.0 (4.5) 15.4 (4.6)
Prader-Willi
Synd.
ACC + P-
OCC
- MEGA- PRESS (Rice, Lagopoulos, Brammer, &
Einfeld, 2016)
• No between-group differences
were observed for GSH.
15(PWS)
15 (HC)
1.0
.Validation
studies
mPFC 7 T PRESS (Choi et al., 2010) Optimized PRESS with sub-TE pair
showed improved selectability of
coupled metabolites (eg, Glu, Gln,
GSH).
mPFC +
rPFC
7 T J-PRESS (An et al., 2015) TE-optimized J-PRESS was shown to
minimize NAA signals while
retaining GSH peak resolution.
Hipp 3 T semi-LASER (Bednařík et al., 2015) Using a short-echo sequence with 5
minutes averaging the GSH CRLB
was kept below 30% in a 4 mL
voxel at 3 T.
ACC 7 T PRESS (Lally et al., 2016) Intra Class Correlation (ICC) using TE-
optimized PRESS both within
sessions (ICC > 0.7) and between
sessions (ICC > 0.6) showed good
repeatability. GSH negatively
associated with age (r = −0.37,
P < .05).
ACC +
PCC
3 T STEAM (Wijtenburg et al., 2014) Short-TE phase rotation STEAM at 3
T showed excellent reproducibility
for GSH: absolute reliability:
SEM < 9.9%, relative reliability:
ICCs 0.42-0.51
Midline
parietal
3 T HERMES (Saleh et al., 2016) HERMES scanning protocol showed
excellent separation of GABA and
GSH. Results agree with MEGA-
PRESS, achieving similar signal-to-
noise ratio in half the time.
mPFC 7 T PRESS (Choi et al., 2010) Optimized PRESS sequence showed
lower CRLBs of Gln and GSH than
with STEAM.
3 T SPECIAL (Schubert, Kühn, Gallinat, Mekle, &
Ittermann, 2017)
Short-TE SPECIAL sequence was used
to measure MRS spectra at 3 T in
21 healthy adults. GSH was
detected with low uncertainty
(CRLB < 30%) in only 16 cases.
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quantification yet used in vivo measurements of GSH concentration
both as a test-bed for novel techniques as well as a means of confirma-
tion of earlier findings. Eighteen of the studies concentrated (at least in
part) on the anterior cingulate cortex (ACC), while the remainder con-
tained a diverse range of regions of interest from the medial (m), dorsal
(d) and posterior (p) PFC (11 studies), hippocampus (Hip: three), occipital
cortex (OCC: four), temporal lobes (Temp: two) and one study each
from the basal ganglia (BG), the thalamus (Th), the midline parietal, the
precuneus (Pre), the left insular LI) and the visual cortex (VI) with addi-
tional studies that performed spectroscopy over an array of voxels, or
chemical shift imaging (CSI). With the exception of CSI, regions were
studied using a single large voxel (of varying size, but generally around
2 × 2 × 2 cm3). Voxels were placed and oriented by a researcher,
guided by a scout scan over the region of interest, and multiple regions
were studied with separate voxels acquired sequentially.
Any patterns of GSH perturbation are difficult to identify, since
there are only a few relevant studies that met our criteria for this
review.
Overall, evidence of altered GSH concentration was inconsistent.
While there were some indications of a decrease in GSH for major
depression, treatments did not alter GSH levels—even when those
treatments were associated with decreased symptoms. However,
these changes are consistent with the changes seen in blood GSH
levels (Maes, Galecki, Chang, & Berk, 2011), providing some support
for a true alteration of GSH systemically. While generally there was
some evidence that GSH levels are perturbed in first-episode psycho-
sis, there was no consistency in the direction of change, and no
changes were observed in either chronic schizophrenia patients or
individuals at clinical high risk for psychosis.
None of the studies of BD included in this review show a change
in brain GSH compared with controls. This may reflect a medication
effect, since lithium (a commonly prescribed mood-stabilizer) has anti-
oxidant properties and most notably can increase GSH in rat cerebral
cells (Cui, Shao, Young, & Wang, 2007). Another interesting point to
consider is the difference between brain GSH and blood GSH in
BD. Studies present conflicting blood and brain GSH data, suggesting
that blood GSH levels are abnormal or perturbed (Gu, Chauhan, &
Chauhan, 2015). This may represent a compensatory response of
GSH production in the brain to balance the depleted peripheral GSH
pool, or may suggest that the two systems are locally regulated via
the GSH-GSSG cycle.
There were some correlational findings between GSH concentra-
tion and clinical variables. For example, in early psychosis, GSH con-
centration in the posterior medial frontal cortex was negatively
correlated with negative symptoms of schizophrenia (Berger et al.,
2008; Demro et al., 2017). Negative symptoms are typically more dif-
ficult to treat with traditional anti-psychotic medication, and this rela-
tionship suggests that an intervention to increase GSH may be a
promising alternative treatment. Similarly, in MD, there was a negative
relationship between GSH and anhedonia. While there were relation-
ships in bipolar disorder between GSH and risky drinking (based on
the alcohol use disorders identification test; Chitty, Kaur, Lagopoulos,
Hickie, & Hermens, 2014; Chitty, Lagopoulos, , Hickie, & Hermens,
2014; Saunders et al., 1993) or smoking. Finally, as a function of age,
a positive relationship was observed between GSH and AD, MCI and
cognitive decline, yet these observations may simply be due to other
age-related effects.
TABLE 1 (Continued)
3 T J-PRESS (Jensen, Auerbach, Pisoni, &
Pizzagalli, 2017)
Test–retest reliability of metabolite
quantification was assessed in a 3 T
shortened J-resolved MRS
sequence in healthy adolecents.
GSH demonstrated satisfactory
reliability with a score
of 8.8–4.1%.
Abbreviations: ACC, anterior cingulate cortex; AD, Alzheimer's disease; AN, anorexia nervosa; ARD, age-related disorder; ASD, autism spectrum disorder;
BD, bipolar disorder; BP, bipolar disorder; BPRS, brief psychiatric rating scale; CAT, catalase; CFS, chronic fatigue syndrome; CRLB, cramer-rao lower
bound; CHR, clinical high risk; CRLB, Cramer Rao lower bound; DD, depressive disorder; DEP, depression; dLPFC, dorsal left prefrontal cortex; dPFC,
dorsolateral prefrontal cortex; EBD, emerging bipolar disorder; EP, early psychosis; EPI, echo-planar imaging; FA, fractional anisotropy; fAD, females with
Alzheimer's disease; FEPPA, tracer; fMCI, females with mild cognitive impairment; FSL, FMRIB software library; GSH, glutathione; GCL, glutamate cysteine
ligase; GABA, gamma-aminobutyric acid; GSSG, glutathione disulphide; HADS, hospital anxiety and depression scale; HC, healthy control; HDRS, hamilton
depression rating scale; HERMES, Hadamard encoding and reconstruction of mega-edited spectroscopy; HIPP, hippocampus; ICC, inferior colliculus; J-
PRESS, J-resolved spectroscopy; LFC, left frontal cortex; LI, left insular; mAD, males with Alzheimer's disease; MCI, mild cognitive impairment; MD, major
depression; MDA, malondialdehyde; MDD, major depressive disorder; mMCI, males with mild cognitive impairment; MMN, mismatch negativity; MRS,
magnetic resonance spectroscopy; MRSI, magnetic resonance spectroscopy imaging; mPFC, medial prefrontal cortex; NAA, n-acetyl aspartate; OCC,
occipital cortex; OCD, obsessive compulsive disorder; PANSS, positive and negative symptom scale; PC, patient controls; PD, psychotic disorder; PFC,
prefrontal cortex; pMFC, posterior medial frontal cortex; PTS, post traumatic stress; PTSD, post traumatic stress disorder; PRESS, point-resolved
spectroscopy; PUT, putamen; PWS, prader-willi syndrome; RFC, right frontal cortex; SA, suicide attempters; SANS, scale for assessment of negative
symptoms; SOD, superoxide dismutase; SEM, standard error of the mean; SIPS, structured interview for psychosis-risk syndromes; STEAM, stimulated
echo acquisition model; SZ, schizophrenia; TBARS, thiobarbituric acid; TE, echo time; THC, tetrahydrocannabinol; TM, mixing time; TSPO, translocator
protein; VC, visual cortex; VT, total distribution volume; YMRS, young mania rating scale.
Summary of findings, describing the clinical group, brain region of interest, magnetic resonance sequence used, study reference and main findings, number
of control vs clinical participants, dmin (the minimum effect size that could be founds significant given the cohorts in each study), and other GSH-specific
correlations that are not directly related to the outcomes of the paper, but important nonetheless.
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3.1.3 | Heterogeneity of studies and the strength of
a brain GSH measurement
The complex nature of psychiatric illness, as well as the difficulty in
GSH measurement, leaves a heterogeneous evidence base that makes
comparison challenging. Contradictions between studies assessing
brain GSH make it difficult to compare brain and blood GSH, where
studies assessing blood GSH present consistent findings in perturba-
tion in GSH metabolism for first-episode psychosis (Fraguas, Díaz-
Caneja, Rodríguez-Quiroga, & Arango, 2017), schizophrenia (Ng, Berk,
Dean, & Bush, 2008), bipolar disorder and autism (Gu et al., 2015).
Medication exposure
Medication status is important to consider as a confounder when
assessing oxidative stress and GSH antioxidant action within youth
mental health. In bipolar disorder, lithium and valproate (commonly
prescribed mood stabilizing drugs) results in a dose-dependent GSH
increase in rat cortical cells. After 1-week chronic treatment, the cells
demonstrated reduced oxidative stress, including increased GSH and
GCL expression (upstream GSH synthesis; Cui et al., 2007). This pre-
sents a new issue, here GSH is elevated as a result of drug administra-
tion, rather than as a result of illness. It is possible the cessation of the
medication would result in a return to the baseline levels of GSH.
Another study looking at first-episode mania in bipolar disorder
(Machado-Vieira et al., 2007) assessed the effects of lithium treatment
vs no-treatment. Antioxidants SOD and CAT were elevated in
unmedicated patients, indicative of generation of reactive species
intrinsic to the illness. Lithium reduced markers of oxidative stress
(TBARS-lipid damage), as well as the SOD/CAT ratio. There is a small
body of evidence associating anti-psychotic and mood-stabilizing
medication with protective effects such as increased antioxidant
enzyme activity or expression, and increased GSH (Cui et al., 2007;
Wang, Xu, Dyck, & Li, 2005). This may have a profound effect on
studies in early psychosis, since not all studies control for drug-naïve
vs medicated patients. The use of a first generation dopamine antago-
nist like haloperidol may contribute to increased oxidative injury
(Lohr, Kuczenski, Bracha, Moir, & Jeste, 1990). In patients with
chronic schizophrenia treated with haloperidol, increased lipid peroxi-
dation markers were observed (TBARS), as well as the antioxidant
enzyme SOD, presumably in response to the peroxidative injury to
membrane phospholipids (Gama, Salvador, Andreazza, Kapczinski, &
Silva Belmonte-de-Abreu, 2006). There are some second-generation
dopamine antagonists that demonstrate protective properties.
Olanzapine, clozapine, quetiapine and risperidone all play a role in
upregulating SOD1 gene expression (Bai et al., 2002), indicative of an
antioxidant response against radical species. The most common treat-
ment for depression, selective-serotonin reuptake inhibitor prescrip-
tion, has resulted in significant reductions in lipid peroxidation as a
marker of oxidative stress (Khanzode, Dakhale, Khanzode, Saoji, &
Palasodkar, 2003). This study found that treatment with fluoxetine
and citalopram decreased serum SOD (antioxidant) and MDA (lipid
peroxidation marker).
Voxel placement
Because there are few studies analysing GSH levels in mental illness
using MRS, there appears to be no “gold standard” voxel location.
There is rationale for the use of the medial frontal cortex due to asso-
ciation of this region with schizophrenia (Pomarol-Clotet et al., 2010).
It has been argued that the medial temporal lobe is a more appropriate
location for spectroscopy since there are reported links with schizo-
phrenia, as well as the regions vulnerability to insult, particularly in the
context of oxidative stress (Wood, Yücel, et al., 2009). The concentra-
tion of GSH in different regions of the brain varies significantly. The
studies that have considered brain GSH have focused on the cortex,
which represents the greatest concentration of brain GSH, with the
cerebellum, hippocampus and striatum following in descending order
of GSH concentration (Kang et al., 1999). The location of GSH in the
brain is highly tissue specific (Rae & Williams, 2017), with a report of
30% higher GSH in cortical white matter (WM) compared with grey
matter dominated PFC (An et al., 2015). Grey matter
(GM) demonstrates increased metabolite concentrations (Srinivasan,
Ratiney, Hammond-Rosenbluth, Pelletier, & Nelson, 2010), and this
tissue also consumes oxygen in a 4:1 ratio to WM, despite only com-
prising 40% of the total brain volume (Mintun et al., 2001), rendering
the GM more susceptible to oxidative insult. When comparing the
frontal cortex of young healthy participants, there was a significantly
greater concentration of GSH in females compared with males
(Mandal et al., 2012), which could provide a confounding factor when
comparing both genders in youth mental health. These results indicate
a significant gender bias towards GSH concentration in the brain,
which may be important considering the greater incidence of schizo-
phrenia and first-episode psychosis (Ochoa, Usall, Cobo, Labad, &
Kulkarni, 2012) in males.
Tobacco and cannabis
The prevalence of smoking in people with mental illness far outweighs
that in the general population. It is estimated in the United Kingdom
that 16% of the general population smoke, whereas in psychosis inci-
dence is 56%, major depression 40%, anxiety 37% and OCD 40%
(Szatkowski & McNeill, 2013). Exogenous administration of nicotine
to isolated cell lines in vivo reduces antioxidant constituents (Yildiz,
Liu, Ercal, & Armstrong, 1999), including GSH. Within a chronic
schizophrenia population, tobacco smoke induces the oxidation of
lipids and proteins (Yao, Leonard, & Reddy, 2006). In bipolar disorder,
GSH concentration is reduced in the ACC of smokers, but not the
non-smoking patients (Chitty, Lagopoulos, et al., 2014), and in a longi-
tudinal study assessing tobacco consumption, a reduction in smoking
was a significant predictor of increased GSH (Chitty, Lagopoulos,
Hickie, & Hermens, 2015a, 2015b).
In marijuana research, it has been reported that brief exposure of
an endothelial cell line to marijuana (3.95%) stimulated increased oxi-
dative stress by 80%, as well as an 81% reduction in GSH concentra-
tion (Sarafian, Magallanes, Shau, Tashkin, & Roth, 1999). In the same
study, exposure to smoke containing no THC (psychoactive compo-
nent of cannabis) resulted in no change in oxidative species, but a
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decline in GSH of 70%. This is interesting since, as with tobacco, mari-
juana use in mental illness is far greater than in the general population
(6.6% (UNDOC, World Drug Report, 2011) compared with 23% in
psychosis (Green, Young, & Kavanagh, 2005), 9.5% in major depres-
sion (Chen, Wagner, & Anthony, 2002), 19% in bipolar disorder
(Marken et al., 1992) and 17% in anxiety (Degenhardt, Hall, &
Lynskey, 2001)).
3.2 | Strength of a brain GSH measure over
periphery
A number of studies have tried to draw comparisons between GSH in
the brain and peripheral measures such as blood components or cere-
brospinal fluid (CSF). Due to the variable nature of study design in the
tissue assessed and the brain region of interest, the concentration of
GSH across differing compartments of the human body is not well
characterized (Richie, Skowronski, Abraham, & Leutzinger, 1996; Sam-
uelsson, Vainikka, & Ollinger, 2011; Sanaei Nezhad, Anton, Parkes,
Deakin, & Williams, 2017)).
Many studies, when investigating GSH, do not differentiate
between reduced, oxidized and total GSH, rendering the measure
comparable only within its own intervention, and difficult to use in
comparison to other studies. This makes the use of MRS as a tool for
GSH quantification useful since the measure is direct, and informative
of brain GSH status.
Blood measures of GSH are the most commonly reported
methods, since assays are cheaper and more accessible than MRS.
Plasma measures of GSH are commonly reported, but report a wide
range of concentrations of GSH (0.5-759 μM) (Nuttall, Martin, Sin-
clair, & Kendall, 1998; Raffa et al., 2009). Plasma acts as a medium for
metabolic waste products in the body, where cells excrete partial pro-
tein and lipid components for clearance. In addition, the role of GSH is
to provide redox balance within a cellular system. Therefore, it is
unlikely that plasma GSH offers a reliable and accurate representation
of peripheral GSH, and even more unlikely that it would be a repre-
sentation of brain GSH.
3.3 | MRS methods
MRS provides a means to explore novel chemical environments and
analyse known molecular systems. Through the analysis of the free
induction decay (FID) spectra of a target nucleus, the local chemical
environment may be inferred. While exotic nuclei, such as 31P and
13C, are possible for targeting in clinical environments, 1H is the most
widely available (Blüml, 2013). However, accurate quantification of
some metabolites is hampered by both the low spatial resolution, due
to the low chemical concentrations and the decreased spectral resolu-
tion of clinical scanners with lower field strengths. Generally, in vivo
MRS is conducted over a single voxel placed within a target brain
region (identified using a preliminary scout scan); while imaging proto-
cols that perform spectroscopy over an array of large voxels are possi-
ble they are less common.
3.4 | GSH measurement in vivo
In vivo quantification of GSH in humans is particularly challenging due
to the low concentration (1.5-3 mmol/L), and the fact that all resonances
overlap with stronger signals from alternate metabolites (De Graaf,
2013). However, it is possible to quantitatively isolate the spectral con-
tribution from GSH through both refinement and calibration of standard
approaches to MRS measurement as well as the development of novel
sequences. Additionally, in order to accurately quantify the contribution
of GSH to the measured spectra, a range of post-processing techniques,
from spectral decomposition to partial volume correction, are required.
While similarities and trends do exist, studies conducted within the past
10 years vary in voxel placement, measurement sequence, acceptance
bounds on signal quality and post-processing methodologies. Here the
predominant approaches are described.
3.5 | Acquisition modalities
In order to accurately estimate the concentration of GSH within a vol-
ume of interest, a range of different tradeoffs must be considered.
The method of spatial localisation utilized is, perhaps, the first consid-
eration, while voxel size and placement, which is affected by field and
tissue homogeneity, are of related concern as are the methods used
to isolate GSH from other contributors.
3.5.1 | Spectroscopy
The FID spectrum exhibits a range of peaks unique to the local elec-
tronic environment of contributing chemical systems. In order to
quantify low concentration metabolites, the extracted spectra must
be of high quality, predominantly assessed through the signal-to-noise
ratio (SNR) and the spectral linewidth (usually expressed in terms of
the full width at half maximum—FWHM). While quantification accu-
racy is usually dependant on the spectral SNR, small linewidths allow
for good separation of distinct peaks. Averaging multiple signals can
increase the SNR, yet patient motion means that shorter scan times
are preferred (both in terms of field homogeneity and partial volume
correction). Approaches to decomposition using basis vectors deter-
mined by contributing metabolites can decrease the importance of
linewidth (removing any requirement of spectral separation), yet the
accuracy to which each contribution can be estimated still relies on
this parameter.
A high-quality shim can be used to provide field (B0) homogeneity
over some region of interest, reducing the expected spectral linewidth
sufficiently for GSH analysis. However, specific sequences are
required in order to localize the induced FID to this region. A number
of different approaches exist, each with competing properties in terms
of measured spectral quality.
3.5.2 | Spatial selectivity
While a range of spatial localisation methods exist, the studies consid-
ered here used point -resolved spectroscopy (PRESS) or stimulated
FISHER ET AL. 11
echo acquisition mode (STEAM), and variants or extensions to these
sequences, almost exclusively.2 PRESS and STEAM both use three
slice selective pulses (Figure 2):
1. PRESS: 1 × 90o + 2 × 180o
2. STEAM: 3 × 90o
STEAM decreases the specific absorption and because there is no
T2 decay in the TM period is preferred for short T2 metabolites, but
this approach does sacrifice the SNR of each acquired spectra.
3.5.3 | Water suppression and spectral editing
Because of the local environment, water suppression is required
in order to resolve the much smaller spectral peaks induced by
the target metabolites. Chemical shift selective and variable pulse
powers and optimized relaxation delays (VAPOUR) are commonly
used for water suppression, while it is also possible to include
water into the macromolecular baseline utilized during molecular
decomposition.
With an accurate high-order shim, it is possible to resolve GSH
peaks directly. However, should the spectral linewidth be too large
(or simply to enhance quantitative accuracy) spectral editing may also
be used to extract specific metabolic signals. The MEscher-GArwood
(MEGA) technique uses editing pulses aimed at spins which are J-
coupled with the spin of interest, for instance, an editing pulse is
applied at 4.56 ppm which targets a α-CH resonance J-coupled to the
desired GSH spins at 2.95 ppm (Saleh et al., 2016). Sequences with
and without editing are subtracted to produce a final spectrum that
contains greatly decreases cross-talk between the spins of interest
and other peaks within the spectra.
3.5.4 | Modifications and extensions
The predominant approach to spectral measurement in the studies
considered here used highly optimized PRESS and STEAM sequences
directly with, in some cases, editing sequences such as MEGA to
home in on specific metabolites. However, a range of those studies
considered also investigated novel spectroscopy acquisition protocols.
Such approaches used relationships involving GSH, tested in vivo, to
not only validate and test the novel protocol, but also to validate and
explore the metabolic relationships.
• Hadamard encoding and reconstruction of mega-edited spectros-
copy: The use of a Hadamard encoding in editing allows the simul-
taneous acquisition of two different voxels and two different
metabolites simultaneously, quartering acquisition time
(or doubling SNR).
• Phase rotation: Phase cycling is introduced into the radio fre-
quency signal to remove undesired spin echo signals, and has been
used with STEAM to isolate the stimulated echo.
• 2D J-differences editing: Two dimensionally resolved MRS pro-
vides spectra over a range of editing frequencies and as such can
be used to perform accurate MRS with no expectation as to the
target metabolite.
• MRS imaging: While direct repetition of PRESS or STEAM for mul-
tiple voxels is possible, imaging (or spatial encoding of the spectro-
scopic signal) is generally conducted using phase encoded gradient
fields.
• Proton echo planar spectroscopic imaging (PEPSI): PEPSI uses an
approach to echo planar imaging, yet one dimension of echos are
encoded with chemical shift information, rather than spatial infor-
mation as in standard EPI. In studies considered that employ PEPSI
large outer volume suppression slabs and advanced approaches to
shimming (FAST(EST)MAP) were required.
3.6 | Data acquisition post-processing
Once the spectra have been acquired, extraction of the GSH signal is
required. Signal extraction can take a number of directions and may
be dependent on the approach taken to measurement. Should suffi-
cient and accurate editing have been conducted, the GSH peak may
then be measured directly (often using simple summation over the
GSH peak). However, in the case that there is residual overlap
between GSH and spectra from other metabolites present in the sam-
ple more sophisticated processing is required.
3.6.1 | Spectral deconvolution
A standard approach, in the case of overlapping peaks, is linear
decomposition of the acquired spectra into metabolic basis functions.
F IGURE 2 Point-resolved
spectroscopy (right) and stimulated echo
acquisition mode (left) sequences, taken
from “In Vivo NMR Spectroscopy,”
(De Graaf, 2013)
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Standard software packages (such as LCModel) are available, or in-
house software may also be used for this approach. In all cases, a
database of metabolic basis functions must be available that are either
carefully measured (with the same system and sequence used for
measurement), simulated using advanced modelling tools such as
GAMMA, VERSI, FID-A (or in-house developed tools) or even a com-
bination of the two where measurements of the macromolecular
spectra may be measured and used in concert with simulated spectra
of specific metabolites.
Once the basis metabolites are identified, they are used to esti-
mate a linear decomposition of the measured spectra (based on some
cost function such as least-squares). The decomposition provides an
estimate of the contribution from each metabolite, while the residual
allows for the presence of missing features to be assessed (ie, it
should represent noise). Generally, such fits also provide a measure of
uncertainty, as a percentage of the Cramer Rao lower bound (CRLB)
in the case of LCModel, which can be used to accept or reject the
measurement. Where acceptance levels were quoted as CRLB, most
commonly >20% uncertainty measurements were rejected, but in
some cases rejection was reserved only for >50% uncertainty. While
it is not clear as to the impact on final values of the estimated value or
its uncertainty, nor rejection levels utilized, using the %CRLB as a
rejection threshold has been shown to be unreliable, particularly for
low concentration metabolites (Kreis, 2016). Kreis (2016) argued that
despite the unreliability of these widely used threshold levels of 20%
to 50%, CRLB is a valuable tool to give an idea of minimal uncer-
tainties in MRS, when the obtained error is understood to be an esti-
mate of the lower bound of the fitting error.
Finally, once the metabolite concentration has been identified, the
voxel heterogeneity was accounted for (in a similar way for most stud-
ies). The MRS voxel (or voxels) used in measurement is segmented
based on the original magnetic resonance imaging image used for
positioning. The contributing volume fractions from GM, WM and
CSF are calculated (often using the FAST4 algorithm from FSL) and
used to correct the measured concentration (or understood as
covariates with this concentration).
3.6.2 | Measurement normalization and post-
processing
Some note should be made regarding the comparison of spectroscopy
techniques across the studies considered here. However, this is made
difficult not only by the broad range of sequences used but also the
range of parameters explored within each sequence. In each study dif-
ferent spectral bandwidths, sampling rates, and number of averages
were considered. Each of these parameters will affect the FWHM and
SNR of the recovered spectra, and hence the reliability of the spectral
decomposition (as will the methods used to generate the basis metab-
olites). Even the units used in measurement of the metabolic concen-
tration differed. While in many studies the absolute GSH
concentration was used as the final measurement, in other studies
GSH as a fraction of total Creatine (tCr) or Water peaks were used.
Finally, comparison across studies that use different scanners is a
potential confound, while the pooling of MRS data is becoming more
important in terms of providing a larger sample size to increase confi-
dence in effect size, or to facilitate collaborative work, the risk of sys-
tematic error is increased, since there is always variability in
participant positioning, partial volume effects and image intensity
inhomogeneity (Stonnington et al., 2008).
Such diversity may not impact the overall neuroscientific findings,
yet each choice will impact the accuracy of each finding, hindering
comparison. No study regarding the impact on quantification of the
relevant tradeoffs has been conducted, so that generally in-house
optimisations and conveniences have been used. While useful for
immediate application, this approach may hinder a standardized
approach for quantitative exploration.
4 | SUMMARY
There is evidence of perturbations in the oxidative stress/antioxidant
response system across youth metal health, with emerging evidence
implicating GSH in the eitiology of mental illness. However, the field
is hampered by highly variable methodology, from basic sequence and
voxel selection to analysis approach and choice of measurement units.
This is before problems surrounding diagnostic heterogeneity are con-
sidered and the simple issue of statistical power. If this area of study
is to progress, studies with larger participant numbers are required,
most probably involving multiple collaborating sites where very close
attention is paid to minimizing between-site variability in both clinical
and spectroscopic data collection.
ENDNOTES
1 Adapted from http://www.djmannion.net/psych_programming/data/
power/power.html
2 Exceptions include spin-echo full-intensity acquired localized spectros-
copy (SPECIAL) and imaging studies.
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